Tremor, hereditary essential, 5

disease
On this page

Also known as essential tremor caused by mutation in TENM4essential tremor, hereditary, 5ETM5TENM4 essential tremortremor, hereditary essential, 5tremor, hereditary essential, type 5

Summary

Tremor, hereditary essential, 5 (MONDO:0014756) is a disease caused by TENM4 (GenCC Strong), with 1 cohort gene.

At a glance

  • Causal gene: TENM4 (GenCC Strong)
  • Cohort genes: 1
  • ClinVar variants: 35

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nametremor, hereditary essential, 5
Mondo IDMONDO:0014756
OMIM616736
DOIDDOID:0111432
UMLSC4225223
MedGen897748
Is cancer (heuristic)no

Also known as: essential tremor caused by mutation in TENM4 · essential tremor, hereditary, 5 · ETM5 · TENM4 essential tremor · tremor, hereditary essential, 5 · tremor, hereditary essential, 5; ETM5 · tremor, hereditary essential, type 5

Data availability: 35 ClinVar variants · 3 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disordermovement disorderessential tremortremor, hereditary essential, 5

Related subtypes (5): tremor, hereditary essential, 1, tremor, hereditary essential, 2, tremor, hereditary essential, 3, tremor, hereditary essential, 4, tremor, hereditary essential, 6

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

35 retrieved; paginated sample, class counts are floors:

25 uncertain significance, 4 conflicting classifications of pathogenicity, 4 benign, 2 pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
1344494NM_001098816.3(TENM4):c.1262C>T (p.Pro421Leu)TENM4Pathogenicno assertion criteria provided
219133NM_001098816.3(TENM4):c.4100C>A (p.Thr1367Asn)TENM4Pathogenicno assertion criteria provided
1192521NM_001098816.3(TENM4):c.5287G>A (p.Gly1763Arg)TENM4Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
2437040NM_001098816.3(TENM4):c.277G>A (p.Gly93Arg)TENM4Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
730091NM_001098816.3(TENM4):c.5545A>G (p.Thr1849Ala)TENM4Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
806721NM_001098816.3(TENM4):c.4895G>A (p.Arg1632His)TENM4Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1031826NM_001098816.3(TENM4):c.346G>A (p.Asp116Asn)TENM4Uncertain significancecriteria provided, single submitter
1319903NM_001098816.3(TENM4):c.4273G>A (p.Asp1425Asn)TENM4Uncertain significancecriteria provided, single submitter
1338998NM_001098816.3(TENM4):c.510G>A (p.Leu170=)TENM4Uncertain significancecriteria provided, single submitter
1711849NM_001098816.3(TENM4):c.1199C>A (p.Pro400His)TENM4Uncertain significancecriteria provided, single submitter
219134NM_001098816.3(TENM4):c.4324G>A (p.Ala1442Thr)TENM4Uncertain significancecriteria provided, single submitter
219135NM_001098816.3(TENM4):c.3412G>A (p.Val1138Met)TENM4Uncertain significancecriteria provided, multiple submitters, no conflicts
2369553NM_001098816.3(TENM4):c.5419G>A (p.Gly1807Ser)TENM4Uncertain significancecriteria provided, multiple submitters, no conflicts
2437035NM_001098816.3(TENM4):c.1471-9_1471-6delTENM4Uncertain significancecriteria provided, single submitter
2437036NM_001098816.3(TENM4):c.1520C>T (p.Ala507Val)TENM4Uncertain significancecriteria provided, single submitter
2437037NM_001098816.3(TENM4):c.1400A>G (p.Asn467Ser)TENM4Uncertain significancecriteria provided, multiple submitters, no conflicts
2437038NM_001098816.3(TENM4):c.7939G>A (p.Val2647Ile)TENM4Uncertain significancecriteria provided, single submitter
2437039NM_001098816.3(TENM4):c.4981_4982del (p.Lys1661fs)TENM4Uncertain significancecriteria provided, single submitter
2437041NM_001098816.3(TENM4):c.553C>T (p.His185Tyr)TENM4Uncertain significancecriteria provided, multiple submitters, no conflicts
2441966NM_001098816.3(TENM4):c.7557C>G (p.Ile2519Met)TENM4Uncertain significancecriteria provided, single submitter
2582627NM_001098816.3(TENM4):c.1126G>A (p.Glu376Lys)TENM4Uncertain significancecriteria provided, single submitter
3255559NM_001098816.3(TENM4):c.905G>A (p.Gly302Glu)TENM4Uncertain significancecriteria provided, single submitter
3341446NM_001098816.3(TENM4):c.2422G>A (p.Gly808Ser)TENM4Uncertain significancecriteria provided, single submitter
3892632NM_001098816.3(TENM4):c.4580A>G (p.Asp1527Gly)TENM4Uncertain significancecriteria provided, single submitter
3892633NM_001098816.3(TENM4):c.6571C>G (p.Arg2191Gly)TENM4Uncertain significancecriteria provided, single submitter
3892634NM_001098816.3(TENM4):c.7547G>A (p.Ser2516Asn)TENM4Uncertain significancecriteria provided, single submitter
4292652NM_001098816.3(TENM4):c.7451A>G (p.Asn2484Ser)TENM4Uncertain significancecriteria provided, single submitter
4540406NM_001098816.3(TENM4):c.4085A>G (p.Tyr1362Cys)TENM4Uncertain significancecriteria provided, single submitter
931031NM_001098816.3(TENM4):c.6668T>C (p.Leu2223Pro)TENM4Uncertain significancecriteria provided, single submitter
931802NM_001098816.3(TENM4):c.4681C>T (p.Arg1561Trp)TENM4Uncertain significancecriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 3 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
TENM4StrongAutosomal dominanttremor, hereditary essential, 53

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
TENM4HGNC:29945ENSG00000149256Q6N022Teneurin-4gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
TENM4Teneurin-4Involved in neural development, regulating the establishment of proper connectivity within the nervous system.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
TENM4Other/UnknownnoEGF, YD, CarboxyPept-like_regulatory

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
ganglionic eminence1
hair follicle1
lateral nuclear group of thalamus1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
TENM4228ubiquitousmarkerhair follicle, ganglionic eminence, lateral nuclear group of thalamus

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
TENM41,409

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
TENM4Q6N0224

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
cardiac cell fate specification18426.0×0.001TENM4
central nervous system myelin formation12407.4×0.002TENM4
positive regulation of gastrulation12407.4×0.002TENM4
gastrulation with mouth forming second1936.2×0.002TENM4
regulation of myelination1887.0×0.002TENM4
positive regulation of myelination1766.0×0.002TENM4
positive regulation of oligodendrocyte differentiation1674.1×0.002TENM4
cardiac muscle cell proliferation1581.1×0.002TENM4
synaptic membrane adhesion1581.1×0.002TENM4
neuron development1255.3×0.004TENM4
signal transduction116.1×0.062TENM4

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
TENM400

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1TENM4

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
TENM40

Clinical trials & evidence

Clinical trials

Clinical trials: 0.